-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, September 26, 2021/PRNewswire/ - WuXi Juno (HKEx code: 2126), an innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products The 24th Chinese Society of Clinical Oncology (CSCO) announced the 1-year follow-up data for the treatment of relapsed/refractory large B-cell lymphoma (r/r LBCL) (RELIANCE study) with Ruiji Orensai injection
The RELIANCE study is a phase II, open, single-arm, multi-center study conducted in China.
Ruiji Orenza injection showed sustained remission and showed long-term survival benefits
Mr.
references:
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C.
About Benoda® (Rigid Orense Injection)
Benoda ® (Rigid Orlens Injection) is a self-developed target CD19 based on the CAR-T cell process platform of Junuo Medical (a Bristol-Myers Squibb company).
About the RELIANCE study (NCT04089215)
The RELIANCE study is a single-arm, multi-center, pivotal study aimed at evaluating the effectiveness and safety of Recchio Lunza injection in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in China Sex
RELIANCE enrolled 59 r/r LBCL patients who had failed second-line therapy including CD20 targeted drugs and anthracyclines, and monitored these patients for up to two years or even longer in order to obtain Long-term results
About WuXi Giant Nuo
WuXi Giant Nuo (HKEx code: 2126) is an innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products
Forward-looking statement
The forward-looking statements contained in this release are based on management’s current expectations and confidence, and there are certain uncertainties or risks that may cause actual results to be substantially different from those described
Source: WuXi Giant Nuo
